Acute myeloid leukemia (AML)
Conditions
Interventions
Intolerant to chemotherapy group:venetocax
Refractory or relapse group:venetocax
Genetically poor prognosis group:venetocax
t-AML group:venetocax
Sponsors
Beijing Children's Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: 1. Patients enrolled in China Children's Leukemia Group (CCLG) - AML2019 study; 2. Patients who are intolerant to chemotherapy; 3. Patients who do not remit from induction therapy, or who have persistently positive MRD after treatment, or whose MRD turn negative and then turn positive again or who have morphological relapse; 4. Patients who have genetic markers of poor prognosis; 5. Patients who have AML induced by chemotherapy/radiotherapy, or who have AML transformed from myelodysplastic syndrome (MDS).
Exclusion criteria
Exclusion criteria: 1. Acute promyelocytic leukemia (APL); 2. Juvenile monocytic leukemia (JMML); 3. Only temporary chemotherapy, radiotherapy or immunotherapy, rather than systematic treatment according to the treatment plan; 4. Had received any antitumor therapy within 2 weeks prior to enrollment, except single dose sheath injection and hydroxy uria or low dose cytarabine for hyperleukaemia; 5. Any comorbidities or mental illnesses with significant abnormalities that affect patient life safety and compliance, informed consent, study participation, follow-up, or interpretation of results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Remission State of Bone Marrow;Minimal Residual Disease;Side Effect of Chemotherapy; | — |
Countries
China
Contacts
Public ContactZheng Huyong
Outcome results
None listed